REGENERON PHARMACEUTICALS, INC.

Regeneron Pharmaceuticals, Inc. is a biotechnology enterprise that discovers, invents, develops, manufactures, and commercializes medicines for serious medical conditions. Its commercial portfolio and clinical pipeline address eye diseases, allergic and inflammatory conditions, oncology, cardiovascular and metabolic disorders, neurological conditions, hematologic conditions, infectious diseases, and rare disorders. Key commercial medicines include EYLEA and EYLEA HD for retinal diseases, Dupixent for inflammatory indications, Libtayo for oncology, and Kevzara for inflammatory arthritis. The company serves patients and medical professionals requiring specialized prescription treatments.

The company markets and distributes its therapies internationally, with product approvals spanning the United States, the European Union, Japan, and other territories. Regeneron supplies commercial medicines both independently and through commercial partnerships across the United States and global markets. The provided text does not state its headquarters location or founding details.

Summary of the business section of Regeneron Pharmaceuticals's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of December 31, 2025, we had 15,410 full-time employees, consisting of 11,961 employed in the United States, 2,149 employed in Ireland, and 1,300 employed in other countries (primarily in the United Kingdom, Japan, and Germany).”